Publication:
Metformin for Obesity in Prepubertal and Pubertal Children: A Randomized Controlled Trial.

Loading...
Thumbnail Image

Date

2017-03-21

Authors

Pastor-Villaescusa, Belen
Cañete, M Dolores
Caballero-Villarraso, Javier
Hoyos, Raul
Latorre, Miriam
Vazquez-Cobela, Rocio
Plaza-Diaz, Julio
Maldonado, Jose
Bueno, Gloria
Leis, Rosaura

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

American Academy of Pediatrics
Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Metformin has shown its effectiveness in treating obesity in adults. However, little research has been conducted in children, with a lack of attention on pubertal status. The objectives were to determine whether oral metformin treatment reduces BMI z score, cardiovascular risk, and inflammation biomarkers in children who are obese depending on pubertal stage and sex. This was a randomized, prospective, double-blind, placebo-controlled, multicenter trial, stratified according to pubertal stage and sex, conducted at 4 Spanish clinical hospitals. Eighty prepubertal and 80 pubertal nondiabetic children who were obese aged 7 to 14 years with a BMI >95th percentiles were recruited. The intervention included 1 g/d of metformin versus placebo for 6 months. The primary outcome was a reduction in BMI z score. Secondary outcomes comprised insulin resistance, cardiovascular risk, and inflammation biomarkers. A total of 140 children completed the study (72 boys). Metformin decreased the BMI z score versus placebo in the prepubertal group (-0.8 and -0.6, respectively; difference, 0.2; P = .04). Significant increments were observed in prepubertal children treated with metformin versus placebo recipients in the quantitative insulin sensitivity check index (0.010 and -0.007; difference, 0.017; P = .01) and the adiponectin-leptin ratio (0.96 and 0.15; difference, 0.81; P = .01) and declines in interferon-γ (-5.6 and 0; difference, 5.6; P = .02) and total plasminogen activator inhibitor-1 (-1.7 and 2.4; difference, 4.1; P = .04). No serious adverse effects were reported. “Metformin decreased the BMI z score and improved inflammatory and cardiovascular-related obesity parameters only in prepubertal children, but a differential effect of metformin was not observed in prepubertal compared to pubertal children. Nevertheless, the doses per kilogram of weight administrated may have had an impact on the metformin effect. Further investigations are necessary.”

Description

MeSH Terms

Child
Double-blind method
Female
Humans
Inflammation
Male
Metformin
Pediatric obesity
Prospective studies
Puberty
Sex factors

DeCS Terms

Metformina
Obesidad infantil
Índice de masa corporal (IMC)
Marcadores de inflamación
Riesgo cardiovascular

CIE Terms

Keywords

Adolescent, Biomarkers, Body mass index, Cardiovascular diseases

Citation

Pastor-Villaescusa B, Cañete MD, Caballero-Villarraso J, Hoyos R, Latorre M, Vázquez-Cobela R, et al. Metformin for Obesity in Prepubertal and Pubertal Children: A Randomized Controlled Trial. Pediatrics. 2017 Jul;140(1):e20164285. doi: 10.1542/peds.2016-4285. Epub 2017 Jun 12. Erratum in: Pediatrics. 2017 Nov;140(5):e20172555